The activity of quinupristin/dalfopristin was compared with that of other widely used antibiotics against 355 strains isolated from patients with endocarditis. MICs were determined by a standard agar dilution method. Quinupristin/dalfopristin was inhibitory at 1 mg/L for all coagulase-negative staphylococci (n = 36) and for the majority of Staphylococcus aureus strains (n = 87). The activity of quinupristin/dalfopristin against 186 viridans streptococci was somewhat dependent on the species, with MIC 50 s ranging from 0.5 to 2 mg/L, being least active against Streptococcus bovis and most active against Streptococcus gordonii and Streptococcus mitis. For the staphylococci, quinupristin/dalfopristin was as active against erythromycin-susceptible as erythromycin-resistant strains. Viridans streptococci showed a slight but significant correlation between sensitivity to erythromycin and quinupristin/dalfopristin. It is concluded that quinupristin/dalfopristin has the potential to treat serious infections such as endocarditis caused by Gram-positive cocci. 
Introduction
Quinupristin/dalfopristin, a recently developed streptogramin antibiotic, is the first of its class available clinically for intravenous use. Most Gram-positive bacteria are susceptible to quinupristin/dalfopristin, [1] [2] [3] and its chief use would be in patients with suspected or proven infections caused by Gram-positive microorganisms, such as soft tissue infections due to streptococci and staphylococci. Since the mechanism of action, and therefore the development of resistance, is distinct from that of presently used antibiotics, 4, 5 it may be particularly useful for treating patients with serious infections due to multi-resistant microorganisms. 6 Another possible indication would be endocarditis due to Gram-positive cocci. These infections are still difficult to treat in many cases, and because of increasing resistance the responsible microorganisms, will be even more difficult to treat in the future. To determine the potential of quinupristin/dalfopristin as treatment for these infections, its activity was compared with that of other frequently used antibiotics against Gram-positive cocci isolated from patients with endocarditis.
Materials and methods

Strains
Strains were isolated from patients with endocarditis in The Netherlands during the period 1 November 1986 to 1 November 1988. These strains have been described extensively. 7 In brief, 419 strains were collected and identified, 326 from native valve endocarditis and 93 from prosthetic valve endocarditis. Of these, 64 were not Gram-positive cocci, or could not be recovered. The remaining 355 strains were used. Strains were identified by standard procedures, 8 as described by van der Meer et al. 7 All viridans streptococci were re-identified using the RAPID ID32 Strep system (bioMérieux, Marcyl'Etoile, France). veen), vancomycin (Eli Lilly, Nieuwegein), rifampicin, penicillin and teicoplanin (Yamanouchi Pharma, Leiderdorp), clindamycin (Upjohn, Amstelveen), clarithromycin and erythromycin (Abbott, Amstelveen), amoxycillin and flucloxacillin (Smith-Kline Beecham, Rijswrijk), cefuroxime (Glaxo, Zeist), cefotaxime (Hoechst-MarionRoussel, Hoevelaken), gentamicin (Schering-Plough, Amstelveen), minocycline (Wyeth-Lederle, Hoofddorp). Stock solutions were prepared according to the recommendations of the National Committee for Clinical Laboratory Standards.
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MIC determination
MICs were determined by a standard agar dilution method. 10 Freshly prepared, serial two-fold dilutions of each antibiotic were incorporated in Mueller-Hinton (Difco, Amsterdam, The Netherlands). Overnight Mueller-Hinton broth cultures of the isolates were adjusted to a turbidity equivalent to a 0.5 McFarland standard and an inoculum of 10 4 cfu was delivered to the surface of the agar plates with a multipoint inoculator. The MIC was defined as the lowest concentration of each antibiotic which inhibited visible growth after incubation for 18 h at 37°C. Three control strains, Staphylococcus aureus ATCC 29213, Streptococcus pneumoniae ATCC 49619 and Enterococcus faecalis ATCC 29212, were included as a control in each batch.
Results were analysed using the SAS computer program package.
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Results
The MIC 50 and MIC 90 and MIC range of quinupristin/ dalfopristin and comparative agents for the bacteria tested are shown in Tables I and II . For staphylococci, quinupristin/dalfopristin was inhibitory at 1 mg/L for all coagulase-negative staphylococci and for the majority of S. aureus strains. Quinupristin/dalfopristin was more active than vancomycin and teicoplanin for the coagulasenegative staphylococci. For -haemolytic streptococci, the activity of quinupristin/dalfopristin was similar to that of vancomycin and slightly less than that of teicoplanin. The two macrolides studied, clarithromycin and erythromycin, were both more active than quinupristin/dalfopristin against these strains. The activity of quinupristin/dalfopristin was not very high for the E. faecalis, the MIC 50 being 8 mg/L; vancomycin and teicoplanin were more active against these isolates. The activity of quinupristin/ dalfopristin against the 186 strains of Streptococcus bovis and viridans streptococci was slightly dependent on the species (Table II) with MIC 50 s ranging from 0.5 to 2 mg/L. Quinupristin/dalfopristin was least active against S. bovis and most active against Streptococcus gordonii and Streptococcus mitis. However, for all species, the range of activity within each species was quite large, indicating much interstrain variability. Except for S. bovis, activity was similar to that of vancomycin, while being less than that of teicoplanin. Quinupristin/dalfopristin was less active than erythromycin and clarithromycin.
Since there is a common target for streptogramins and macrolides, 12 potential cross-resistance between erythromycin and quinupristin/dalfopristin was examined amongst staphylococci and the viridans streptococci (Table III) . For the staphylococci, there appeared to be no cross-resistance. The majority of both erythromycinsusceptible and erythromycin-resistant isolates were inhibited by quinupristin/dalfopristin at concentrations of 1 mg/L. In contrast, erythromycin-resistant strains of viridans streptococci were slightly less sensitive than erythromycin-sensitive strains. Correlation analysis between susceptibility of erythromycin and quinupristin/ dalfopristin showed statistical significance (r 0.174; P 0.02).
Discussion
This study showed that quinupristin/dalfopristin is active against staphylococci and streptococci isolated from patients with endocarditis, the only exception being E. faecalis, which appeared only moderately susceptible. The majority of the strains were susceptible to concentrations achieved in vivo, 13 and quinupristin/dalfopristin could therefore be a suitable agent for treating infections due to staphylococci and streptococci. The somewhat lower activity against E. faecalis has been found by other workers. 14 The range of activity was large, however, and there might be occasions when the drug could be used. The alternative agents, vancomycin and teicoplanin, have similar activity, with teicoplanin being slightly more active. One of the disadvantages of the glycopeptides for treating endocarditis, however, is that these molecules are large, and their penetration into vegetations is not optimal. 15 However, in a rabbit model of aortic valve endocarditis, vancomycin was slightly more active than quinupristin/ dalfopristin. 16 For clinical use quinupristin/ dalfopristin may be an alternative in patients with endocarditis due to Gram-positive cocci that cannot be treated with standard therapy with -lactam antibiotics. Although we tested no methicillin-resistant isolates in this study, other studies have shown similar activity of quinupristin/ dalfopristin against methicillin-and susceptible-resistant staphylococci. 2, 17, 18 The streptogramins, lincosamides and macrolides have a common target, namely the 23S ribosomal RNA. 12 Different mechanisms of resistance have been described. [19] [20] [21] To determine whether there was cross-resistance between quinupristin/dalfopristin and the macrolides, we looked at the susceptibility of quinupristin/dalfopristin in erythromycin-susceptible and erythromycin-resistant strains. For staphylococci, we found no difference between these Hence quinupristin/dalfopristin may be used in treating infections due to erythromycin-resistant strains, 2 despite known cross-resistance between erythromycin and quinupristin. For the viridans streptococci, there was a difference between erythromycin-resistant and erythromycin-susceptible strains with respect to susceptibility to quinupristin/dalfopristin, shown both by the difference in susceptibility between the two groups and a correlation between susceptibility to erythromycin and to quinupristin/dalfopristin. The same was true for clarithromycin (results not shown). This suggests that there is some form of cross-resistance between these agents, probably dependent on the mechanism of resistance of the individual strain (as indicated by the low correlation (r 0.174), significant only because of the large number of strains tested).
It may be concluded that quinupristin/dalfopristin is a potential therapeutic agent for serious infections, such as endocarditis, due to Gram-positive cocci. Although crossresistance to macrolides in viridans streptococci is low, susceptibility of individual strains should be taken into account when considering its use in the treatment of infections. Further clinical studies should be undertaken to determine its role in the treatment of patients with endocarditis due to Gram-positive cocci.
